Whicher CA, Price HC, Phiri P, et al. - Relative to the general population, people with severe mental illness are at higher risk of being overweight and obese, so researchers here examined the feasibility and acceptability of using liraglutide 3.0 mg daily to address this problem via a double‐blind, randomized, placebo‐controlled pilot trial. Participants in the study were adults with schizophrenia, schizoaffective, or first‐episode psychosis who were prescribed antipsychotic medication and were overweight or obese. They were randomized 47 participants to receive once daily subcutaneous liraglutide or placebo, titrated to 3.0 mg daily, for 6 months. Participants in the liraglutide arm exhibited mean weight reduction of 5.7±7.9 kg vs no significant weight change in the placebo group. The intervention group showed a reduction in BMI, waist circumference and HbA_1c. In the management of obesity in people with severe mental illness, findings overall support the necessity for a larger randomized controlled trial examining the utility of liraglutide (maximum dose 3.0 mg daily).